Welcome to our dedicated page for Hinge Health SEC filings (Ticker: HNGE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to Hinge Health, Inc. (NYSE: HNGE) SEC filings, giving investors and researchers a primary source for the company’s regulatory disclosures. As a public company in the healthcare and health information services space, Hinge Health uses its filings to report financial results, describe material events, and document key corporate actions.
Current and prospective shareholders can review periodic reports and current reports on Form 8-K that summarize important developments. Recent 8-K filings have covered topics such as quarterly financial results, the use of non-GAAP financial measures, and the authorization of a share repurchase program for the company’s Class A common stock. These filings often reference accompanying press releases that provide detailed financial statements, reconciliations of non-GAAP metrics, and information about earnings conference calls.
Other 8-K disclosures describe events related to the company’s initial public offering, including lock-up agreements that restrict the sale or transfer of shares for a defined period and the conditions under which certain shares become eligible for earlier release. Such filings help investors understand share supply dynamics, insider selling restrictions, and the timing of potential changes in the public float.
Through its SEC reports, Hinge Health also explains how it presents metrics like calculated billings and discusses the seasonality associated with client launches and platform access. These documents complement the company’s press releases about its AI-powered musculoskeletal care platform, wearable devices, and clinician-supported programs by providing audited or reviewed financial data and formal regulatory context.
On Stock Titan, SEC filings for HNGE are updated as they are posted to the EDGAR system. AI-powered tools can help summarize lengthy documents, highlight key figures, and surface important sections, such as discussions of results of operations, share repurchase details, and other material events disclosed in Hinge Health’s filings.
Hinge Health, Inc. ownership filing: HANSAINVEST Hanseatische Investment-Limited Co reports beneficial ownership of 1,476,600 ordinary shares, representing 2.65% of Hinge Health's class of ordinary shares. The ownership figure is stated as of December 31, 2025 and the Schedule 13G was signed on April 27, 2026.
The filing states HANSAINVEST has sole voting and dispositive power over the shares under German law (Sec. 93 (1) KAGB) and notes the shares are held for the account of investment funds managed by HANSAINVEST.
Hinge Health, Inc. executive chairman and co-founder Gabriel M.I. Mecklenburg reported an insider transaction involving a conversion and sale of shares. He converted 33,333 shares of Class B Common Stock into Class A Common Stock and then sold 33,333 Class A shares in an open-market transaction at a weighted average price of $45.0463 per share, with prices ranging from $45.00 to $45.44, under a pre-arranged Rule 10b5-1 trading plan adopted on December 1, 2025. After these transactions, he reported direct ownership of 1,759,769 shares of Class B Common Stock and indirect Class B holdings convertible into 383,592 Class A shares through a family trust and 1,092,119 Class A shares through a GRAT, plus an additional 944,250 performance stock units that are excluded from the reported amounts.
Hinge Health, Inc. is holding its 2026 annual stockholder meeting virtually on June 3, 2026 at 9:00 a.m. Pacific Time. Stockholders of record as of April 10, 2026 can vote on electing two Class I directors, Teddie Wardi and Tyler Sloat, to terms ending at the 2029 meeting and on ratifying Deloitte & Touche LLP as independent auditor for 2026.
The company highlights that a majority of directors and all board committees are independent, and describes extensive risk oversight, cybersecurity, and executive compensation programs. The proxy also details significant 2025 equity-based pay for senior executives and the structure of director retainers and RSU grants.
Hinge Health, Inc. director Tyler Sloat acquired 68 shares of Class A Common Stock through the settlement of fully vested restricted stock units on April 5, 2026. These RSUs were granted in lieu of quarterly cash retainers under the company’s Non-Employee Director Compensation Program. Following this equity grant, Sloat directly holds 9,964 Class A shares.
Hinge Health, Inc. executive chairman and co-founder Gabriel M.I. Mecklenburg converted 50,000 shares of Class B Common Stock into 50,000 shares of Class A Common Stock and then sold all of those Class A shares in open-market transactions.
The sales covered 49,332 shares at a weighted average of $38.448 and 668 shares at a weighted average of $39.0167, executed under a pre-arranged Rule 10b5-1 trading plan adopted on December 1, 2025. Following these trades, he held no Class A shares directly but continued to hold 1,793,102 Class B shares directly, plus additional Class B shares through a GRAT and a family trust that are convertible into over 1.47 million Class A shares. The filing also notes 944,250 performance stock units held by Mecklenburg, which are excluded from the share totals.
Hinge Health, Inc. President James Pursley reported a routine tax-related share disposition. On this Form 4, 831 shares of Class A Common Stock were withheld and cancelled at a value of $38.56 per share to cover federal and state tax withholding from the vesting of restricted stock units. After this transaction, Pursley directly holds 731,273 shares of Hinge Health Class A Common Stock.
Hinge Health, Inc. Chief Financial Officer James Budge reported a disposition of 4,614 shares of Class A Common Stock on a tax-withholding basis. The shares were relinquished to the company at $38.56 per share to cover federal and state tax obligations from vesting restricted stock units. Following this exempt transaction under Section 16b-3(e), Budge directly holds 396,813 shares of Class A Common Stock.
Hinge Health Inc disclosure: The Vanguard Group filed an amendment reporting 0 shares beneficially owned of Hinge Health common stock, representing 0% of the class. The amendment explains an internal realignment effective January 12, 2026, causing certain Vanguard subsidiaries to report separately.
The filing is signed by Ashley Grim, Head of Global Fund Administration, dated 03/27/2026. The report states Vanguard and related investment vehicles retain the right to receive dividends or sale proceeds where applicable; no single other person holds >5% of the class according to the filing.
Hinge Health, Inc. Chief Financial Officer James Budge reported selling a total of 11,006 shares of Class A Common Stock on March 23, 2026 in three open-market transactions. The reported weighted average sale prices were $41.2858, $42.4514 and $42.8023 per share, each with specified intraday price ranges.
These sales were effected under a Rule 10b5-1 trading plan adopted by Budge on June 12, 2025, indicating they were pre-arranged. Following the transactions, he directly owns 401,427 shares of Hinge Health Class A Common Stock.